Fondazione Cellule Staminali Report issue

Foundation Phase 1

Organization Overview

First Clinical Trial
2017
NCT03282760
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Fondazione Cellule Staminali

Active Ingredients

Drugs in Phase 1 Trials (1)

autologous mesenchymal stem cell-derived neural progenitors (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Multiple Sclerosis (Phase 1)

Multiple Sclerosis, Chronic Progressive (Phase 1)

Neoplasm Metastasis (Phase 1)

Sclerosis (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 1